Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRSJ49)

Drug Name
IL-18BP Drug Info
Indication
Disease Entry ICD 11 Status REF
B-cell non-hodgkin lymphoma 2B33.5 Discontinued in Phase 1 [1]
Rheumatoid arthritis FA20 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMRSJ49

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin-18 (IL18)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tadekinig alfa DM1NTVQ XIAP deficiency 4A01.22 Phase 3 [3]
GSK-1070806 DMQGPLO Type-2 diabetes 5A11 Phase 2 [4]
MEDI-2338 DMCMYPX Chronic obstructive pulmonary disease CA22 Phase 1 [5]
Iboctadekin DMHS29U Non-hodgkin lymphoma 2B33.5 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-18 (IL18) TTRICUF IL18_HUMAN Binder [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013227)
2 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
3 Clinical pipeline report, company report or official report of AB2 Bio.
4 Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220.
5 Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 397-412.
6 Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78.